This December, Afrezza, MannKind's ( MNKD) inhalable insulin therapy for prandial (meal-time) management of blood glucose in diabetics, faces FDA decision. Afrezza's path to approval is well worn and ...

A headline incorrectly stated that Pfizer will buy rights for Exubera inhaled insulin from San Carlos biotech company Nektar Therapeutics. Pfizer actually paid to end its marketing of Exubera. The ...

What if patients with type 1 diabetes mellitus (T1DM) could be freed from needles, vials, and syringes? What if insulin didn’t have to be injected, but instead could be inhaled, like an asthma ...

A new formulation of insulin that is delivered via inhaler promises the elimination of needles for patients with diabetes. So why hasn't there been more fanfare over the anticipated arrival of ...

MannKind Corporation made a big splash last week with a press release announcing that its inhaled insulin product, Afrezza, had successfully completed two phase 3 clinical trials designed to support ...

Jan. 27, 2006 — The first inhaled insulin ( Exubera) was approved today by the US Food and Drug Administration (FDA) for the treatment of adult patients with type 1 and type 2 diabetes. An inhaled ...